The treatment was generally well tolerated, with only minimal toxicity observed.<h4>Discussion</h4>This study demonstrates that TLK2 ASO is a promising therapeutic strategy for AML, particularly in combination with FLT3 inhibition, and may apply to other TLK2-driven cancers. Here, FLT3 is linked to acute myeloid leukemia.